OXIS International, Inc. (OTCMKTS:OXIS) stated that trading in its common stock resumed on Euronext Paris effective April 14, 2015. The shares now trade in a new mode known as “double call auction trading mode”. It is a fixed trading mode different from the previous continuous trading mode that was applicable on OXIS stock.
Expressing his views on the new trading mode on Euronext Paris Anthony Cataldo, the CEO said that the new trading way will encourage efficient trading across the company’s markets on both the OTC Bulletin Board as well as on Euronext. The recent change has received approval from Euronext Paris.
Business of Biotech
In unrelated news, the CEO of OXIS confirmed that he will be a part of Business of Biotech conference to be held on April 17, 2015. It is organized at the Moffitt Cancer Center in Florida. The conference highlights on concept of “Collaborate to Innovate.”
In the upcoming ninth conference of Business of Biotech, Cataldo will highlight the latest trend and developments related to raising funds. He will talk about the different fundraising options and changes witnessed by evolving life science firms. The conference will also have executives from other renowned firms like Signal Genetics Inc (NASDAQ:SGNL), Cvergenx, Lion Biotechnologies Inc (NASDAQ:LBIO) and MetaStat Inc (OTCMKTS:MTST). They will also be a part of the panel.
Expressing his views on the upcoming conference, Cataldo stated that he look forward to become a part of the important conference. OXIS is well-placed in the industry to take a step ahead with its advanced technologies. They are at cutting-edge of immunotherapeutics in the cancer therapies markets.
In last trading session, the share price of OXIS jumped 6.67% to close the trading session at $0.0320 on share volume of 13.50 million much higher than the average volume of 5.07 million.